Angiotensin II-induced reduction in exercise capacity is associated with increased oxidative stress in skeletal muscle

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 302, Issue 5, 2012, Pages

  Inoue, Naoki ^a   Kinugawa, Shintaro ^a   Suga, Tadashi ^a   Yokota, Takashi ^a   Hirabayashi, Kagami ^a   Kuroda, Satoshi ^a   Okita, Koichi ^b   Tsutsui, Hiroyuki ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKUSHO UNIVERSITY   (Japan)

Author keywords

Mitochondria; Oxygen uptake; Reduced nicotinamide adenine dinucleotide phosphatase oxidase

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN III; APOCYNIN; DRINKING WATER; LUCIGENIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; ACETOPHENONE DERIVATIVE; ANTIOXIDANT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENERGY METABOLISM; ENZYME ACTIVITY; EXERCISE; HEART FUNCTION; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; MUSCLE MASS; MUSCLE METABOLISM; MUSCLE MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SKELETAL MUSCLE; TREADMILL EXERCISE; ANIMAL; BREATH ANALYSIS; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; EXERCISE TOLERANCE; METABOLISM; OXYGEN CONSUMPTION; PHYSIOLOGY;

ACETOPHENONES; ANGIOTENSIN II; ANIMALS; ANTIOXIDANTS; BREATH TESTS; EXERCISE TOLERANCE; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA, MUSCLE; MUSCLE, SKELETAL; NADPH OXIDASE; OXIDATIVE STRESS; OXYGEN CONSUMPTION; SUPEROXIDES;

EID: 84857275742     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00534.2011     Document Type: Article

References (39)

1. Aldieri E, Riganti C, Polimeni M, Gazzano E, Lussiana C, Campia I, Ghigo D. Classical inhibitors of NOX NAD(P)H oxidases are not specific. Curr Drug Metab 9: 686-696, 2008.
2. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 105: 293-296, 2002.
3. Brown GC. The leaks and slips of bioenergetic membranes. FASEB J 6: 2961-2965, 1992.
4. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 116: 205-219, 2004.
5. Drexler H, Banhardt U, Meinertz T, Wollschlager H, Lehmann M, Just H. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind, placebo-controlled trial. Circulation 79: 491-502, 1989.
6. Drexler H, Riede U, Munzel T, Konig H, Funke E, Just H. Alterations of skeletal muscle in chronic heart failure. Circulation 85: 1751-1759, 1992.
7. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82: 1724-1729, 1990.
8. Freund C, Schmidt-Ullrich R, Baurand A, Dunger S, Schneider W, Loser P, El-Jamali A, Dietz R, Scheidereit C, Bergmann MW. Requirement of nuclear factor-kappaB in angiotensin II- and isoproterenolinduced cardiac hypertrophy in vivo. Circulation 111: 2319-2325, 2005.
9. Goodell S, Cortopassi G. Analysis of oxygen consumption and mitochondrial permeability with age in mice. Mech Ageing Dev 101: 245-256, 1998.
10. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74: 1141-1148, 1994.
11. Heumuller S, Wind S, Barbosa-Sicard E, Schmidt HH, Busse R, Schroder K, Brandes RP. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 51: 211-217, 2008.
12. Javesghani D, Magder SA, Barreiro E, Quinn MT, Hussain SN. Molecular characterization of a superoxide-generating NAD(P)H oxidase in the ventilatory muscles. Am J Respir Crit Care Med 165: 412-418, 2002.
13. Kawano S, Kubota T, Monden Y, Kawamura N, Tsutsui H, Takeshita A, Sunagawa K. Blockade of NF-kappaB ameliorates myocardial hypertrophy in response to chronic infusion of angiotensin II. Cardiovasc Res 67: 689-698, 2005.
14. Kerner J, Turkaly PJ, Minkler PE, Hoppel CL. Aging skeletal muscle mitochondria in the rat: decreased uncoupling protein-3 content. Am J Physiol Endocrinol Metab 281: E1054-E1062, 2001.
15. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52: 11-34, 2000.
16. Kinugawa S, Wang Z, Kaminski PM, Wolin MS, Edwards JG, Kaley G, Hintze TH. Limited exercise capacity in heterozygous manganese superoxide dismutase gene-knockout mice: roles of superoxide anion and nitric oxide. Circulation 111: 1480-1486, 2005.
17. 2 during maximal cycle ergometry. J Appl Physiol 73: 1114-1121, 1992.
18. Lang D, Mosfer SI, Shakesby A, Donaldson F, Lewis MJ. Coronary microvascular endothelial cell redox state in left ventricular hypertrophy: the role of angiotensin II. Circ Res 86: 463-469, 2000.
19. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 83: 778-786, 1991.
20. Matsui Y, Jia N, Okamoto H, Kon S, Onozuka H, Akino M, Liu L, Morimoto J, Rittling SR, Denhardt D, Kitabatake A, Uede T. Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 43: 1195-1201, 2004.
21. Matsushima S, Kinugawa S, Yokota T, Inoue N, Ohta Y, Hamaguchi S, Tsutsui H. Increased myocardial NAD(P)H oxidase-derived superoxide causes the exacerbation of postinfarct heart failure in type 2 diabetes. Am J Physiol Heart Circ Physiol 297: H409-H416, 2009.
22. Minami N, Li Y, Guo Q, Kawamura T, Mori N, Nagasaka M, Ogawa M, Ito O, Kurosawa H, Kanazawa M, Kohzuki M. Effects of angiotensin- converting enzyme inhibitor and exercise training on exercise capacity and skeletal muscle. J Hypertens 25: 1241-1248, 2007.
23. Murdoch CE, Grieve DJ, Cave AC, Looi YH, Shah AM. NADPH oxidase and heart failure. Curr Opin Pharmacol 6: 148-153, 2006.
24. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 346: 793-801, 2002.
25. Ojaimi C, Li W, Kinugawa S, Post H, Csiszar A, Pacher P, Kaley G, Hintze TH. Transcriptional basis for exercise limitation in male eNOSknockout mice with age: heart failure and the fetal phenotype. Am J Physiol Heart Circ Physiol 289: H1399-H1407, 2005.
26. Okita K, Yonezawa K, Nishijima H, Hanada A, Ohtsubo M, Kohya T, Murakami T, Kitabatake A. Skeletal muscle metabolism limits exercise capacity in patients with chronic heart failure. Circulation 98: 1886-1891, 1998.
27. Silveira LR, Pilegaard H, Kusuhara K, Curi R, Hellsten Y. The contraction induced increase in gene expression of peroxisome proliferator- activated receptor (PPAR)-gamma coactivator 1alpha (PGC-1alpha), mitochondrial uncoupling protein 3 (UCP3) and hexokinase II (HKII) in primary rat skeletal muscle cells is dependent on reactive oxygen species. Biochim Biophys Acta 1763: 969-976, 2006.
28. Song YH, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 115: 451-458, 2005.
29. Suematsu N, Tsutsui H, Wen J, Kang D, Ikeuchi M, Ide T, Hayashidani S, Shiomi T, Kubota T, Hamasaki N, Takeshita A. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 107: 1418-1423, 2003.
30. Sullivan MJ, Green HJ, Cobb FR. Altered skeletal muscle metabolic response to exercise in chronic heart failure. Relation to skeletal muscle aerobic enzyme activity. Circulation 84: 1597-1607, 1991.
31. Tsutsui H, Ide T, Hayashidani S, Suematsu N, Shiomi T, Wen J, Nakamura K, Ichikawa K, Utsumi H, Takeshita A. Enhanced generation of reactive oxygen species in the limb skeletal muscles from a murine infarct model of heart failure. Circulation 104: 134-136, 2001.
32. Vejrazka M, Micek R, Stipek S. Apocynin inhibits NADPH oxidase in phagocytes but stimulates ROS production in non-phagocytic cells. Biochim Biophys Acta 1722: 143-147, 2005.
33. Ventura-Clapier R, Kuznetsov A, Veksler V, Boehm E, Anflous K. Functional coupling of creatine kinases in muscles: species and tissue specificity. Mol Cell Biochem 184: 231-247, 1998.
34. White WB, McCabe EJ, Hager WD, Schulman P. The effects of the long-acting angiotensin-converting enzyme inhibitor cilazapril on casual, exercise, and ambulatory blood pressure. Clin Pharmacol Ther 44: 173-178, 1988.
35. Yokota T, Kinugawa S, Hirabayashi K, Matsushima S, Inoue N, Ohta Y, Hamaguchi S, Sobirin MA, Ono T, Suga T, Kuroda S, Tanaka S, Terasaki F, Okita K, Tsutsui H. Oxidative stress in skeletal muscle impairs mitochondrial respiration and limits exercise capacity in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 297: H1069-H1077, 2009.
36. Yu J, Weiwer M, Linhardt RJ, Dordick JS. The role of the methoxyphenol apocynin, a vascular NADPH oxidase inhibitor, as a chemopreventative agent in the potential treatment of cardiovascular diseases. Curr Vasc Pharmacol 6: 204-217, 2008.
37. Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, Loibner H, Wang XH, Penninger JM, Kassiri Z, Oudit GY. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122: 717-728, 2010.
38. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta 1241: 139-176, 1995.
39. Zou B, Suwa M, Nakano H, Higaki Y, Ito T, Katsuta S, Kumagai S. Decreased serum leptin and muscle oxidative enzyme activity with a dietary loss of intra-abdominal fat in rats. J Nutr Biochem 15: 24-29, 2004